Dexlansoprazole is a proton pump inhibitor. Proton pump inhibitors are benzimidazole derivatives that act specifically and non-competitively on H+/K+-ATPase to treat peptic ulcers. Proton pump inhibitors are mostly fat-soluble weakly alkaline. After being absorbed into the blood, they enter the acidic environment of the parietal cell secretory tubules and tubulovesicular cavities. The activation products are generally active subsulfonic acids and subsulfonamides, which couple with the thiol group of H+-K+-ATPase to form an irreversible covalent disulfide bond, blocking the H+-K+ transport mechanism, thereby inhibiting gastric acid secretion.
Let us work together to protect precious health